Skip to main content
SpringerLink
Log in

Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain

  • DISCUSSION
  • Published:
Pharmaceutical Chemistry Journal Aims and scope

Second-generation antipsychotic substances, as compared with first-generation antipsychotics, are more effective in relation to psychotic symptoms and have significantly lower potential for developing extrapyramidal impairments such as parkinsonism and late dyskinesia. However, use of these agents is associated with significant weight gain in patients. Advances in the pharmacogenetics of antipsychotic-induced weight gain are analyzed here.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. P. R. Gavin and O. O. McGowan, J. Psychopharmacol., 31(11), 1430 – 1436 (2017).

  2. M. De Hert, J. M. Dekker, D. Wood, et al., Eur. Psychiatry, 24, 412 – 424 (2009).

  3. S. J. Cooper, G. P. Reynolds, T. Barnes, et al., J. Psychopharmacol., 30, 717 – 748 (2016).

  4. R. H. Liu, M. Mizuta, and S. Matsukura., Eur. J. Pharmacol., 458(1 – 2), 227 – 233 (2003).

  5. K. K. Harris, M. Zope, and T. C. Friedman., Nat. Rev. Endocrinol., 12(5), 299 – 308 (2016).

  6. E. M. Denisov, Zh. Psikhiatrii Med. Psikhol., No. 1 – 2 (24 – 25), 151 – 160 (2010).

  7. D. J. Müller and J. L. Kennedy, Pharmacogenomics, 7(6), 863 – 887 (2006).

  8. C. Rummel-Kluge, K. Komossa, S. Schwarz, et al., Schizophr. Res., 123, 225 – 233 (2010).

  9. S. Leucht, A. Cipriani, L. Spineli, et al., Lancet, 382, 951 – 962 (2013).

  10. A. J. Risselada, H. Mulder, and R. Eibert, Pharmacogenomics, 12(8), 1213 – 1227 (2011).

  11. K. Vasudev, Can. J. Psychiatry, 62(2), 138 – 149 (2017).

  12. R. R. MacNeil and D. J. Müller, Molecular. Neuropsychiatry, 2(2), 61 – 78 (2016).

  13. S. Gebhardt, F. M. Theisen, M. Haberhausen, et al., J. Clin. Pharm. Ther., 35, 207 – 211 (2010).

  14. S. Kapur and D. Mamo, Prog. Neuro-Psychoph., 27, No. 7, 1081 – 1090 (2003).

  15. A. A. Verhaegen and L. F. Van Gaal, J. Endocrinol. Invest., 40, No. 11, 1165 – 1174 (2017).

  16. T. A. P. Lett, T. J. M. Wallace, and N. I. Chowdhury, Molec. Psychiatry, 17, 242 – 266 (2012).

  17. Z. Jian-Ping and K. Anil, Expert. Opin. Drug Metab. Toxicol., 7, No. 1, 9 – 37 (2011).

  18. V. S. Basile, M. Masellis, R. S McIntyre, et al., J. Clin. Psychiatry, 62(S23), 45 – 66 (2001).

  19. L. Tecott, L. Sun, S. F. Akana, et al., Nature, 374, 542 – 546 (1995).

  20. M. N. Sicard, C. C. Zai, A. K. Tiwari, et al. Pharmacogenomics, 11, 1561 – 1571 (2010).

  21. H. Y. Lane, Y. C. Liu, and C. L. Huang, J. Clin. Psychopharmacol., 26, 128 – 134 (2006).

  22. D. A. Wirshing, W. C. Wirshing, L. Kysar, et al., J. Clin. Psychiatry, 60, 358 – 363 (1999).

  23. Postgenomic and Nanotechnology Innovations (2003 – 2014) [in Russian], [Online resource] URL: http: // xn–h1aaoah. xn–p1ai / information / genes-information / 145.html (date accessed August 24, 2018).

  24. X. Y. Zhang, Y. L. Tan, D. F. Zhou, et al., J. Clin. Psychopharmacol., 27, 246 – 251 (2007).

  25. C. A. Calarge, V. L. Ellingrod, B. Zimmerman, et al., Psychiatric Gen., 19, 320 – 327 (2009).

  26. O. O. Yevtushenko, S. J. Cooper, R. O’Neill, et al., Br. J. Psychiatry, 192, 424 – 428 (2008).

  27. A. K. Malhotra, C. U. Correll, N. I. Chowdhury, et al., Arch. Gen. Psychiatry, 69(9), 904 – 912 (2012).

  28. F. Czerwensky, S. Leucht, and W. Steimer, J. Clin. Psychopharmacol., 33, 74 – 79 (2013).

  29. N. I. Chowdhury, A. K. Tiwari, R. P. Souza, et al., Pharmacogenomics J., 13(3), 272 – 279 (2013).

  30. A. K. Tiwari, E. J. Brandl, and C. C. Zai, World J. Biol. Psychiatry, 17(3), 221 – 229 (2016).

  31. C. C. Zai, A. K. Tiwari, and G. C. Zai, Cur. Opin. Psychiatry, 31(3), 200 – 212 (2018).

  32. C. Bousman, J. Allen, and H. A. Eyre, Am. J. Psychiatry, 175, 189 (2018).

  33. S. H. Preskorn, J. Psychiatr. Pract., 19, 397 – 405 (2013).

Download references

Author information

Authors and Affiliations

  1. Ministry of Health of the Russian Federation, Scientific Center for Expert Evaluation of Medicinal Products, Building 2, 8 Petrovskii Boulevard, 127051, Moscow, Russia

    E. O. Zhuravleva, N. Yu. Vel’ts, I. I. Snegireva, G. V. Kutekhova & R. N. Alyautdin

Authors
  1. E. O. Zhuravleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Yu. Vel’ts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. I. Snegireva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. V. Kutekhova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. N. Alyautdin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. O. Zhuravleva.

Additional information

Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol, 53, No, 7, pp, 59 – 62, July, 2019.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhuravleva, E.O., Vel’ts, N.Y., Snegireva, I.I. et al. Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain. Pharm Chem J 53, 668–671 (2019). https://doi.org/10.1007/s11094-019-02059-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-019-02059-z

Keywords

Search

Navigation